12 June 2023 in Respiratory Medicine
The clinical spectrum of connective tissue disease-associated interstitial lung disease (CTD-ILD) and rheumatoid arthritis-associated interstitial lung disease (RA-ILD) ranges from asymptomatic findings on radiographic imaging to a rapidly progressive illness leading to respiratory failure and death. The treatment is always challenging due to the paucity of proven effective treatments. Nintedanib and pirfenidone are recently approved antifibrotics in idiopathic pulmonary fibrosis. This study aimed to investigate the efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD. Relevant databases were searched for randomized controlled trials that compared pirfenidone or nintedanib with placebo in patients with CTD-ILD and RA-ILD. The primary outcome was the change in forced vital capacity (FVC). The odds ratio or risk ratio with 95% confidence interval (CI) was estimated for categorical data, and the mean difference with 95% CI was estimated for continuous data. The I2 statistic was used to assess heterogeneity, and meta-analysis was performed when possible. Ten studies with a total of 880 participants met the inclusion criteria. Of these, four studies were included in the meta-analysis. According to the pooled result, the annual decline of FVC was significantly decreased in the antifibrotic agent arm compared to that in the placebo arm (MD 70.58 mL/yr, 95% CI 40.55 to 100.61). This review suggests a potential benefit and safety of antifibrotic treatment in slowing the decline of FVC in patients with CTD-ILD and RA-ILD. Further large-sample, random-controlled, high-quality trials are needed to provide more evidence in the decision-making regarding the use of antifibrotics in this group of patients. PROSPERO; No: CRD42022369112; URL: https://www.crd.york.ac.uk/prospero/.
17 March 2020 in CNS Neuroscience & Therapeutics
Click on the article title to read more.
1 January 2026 in Mediators of Inflammation
Background: The C‐reactive protein–albumin–lymphocyte (CALLY) index, a novel composite marker derived from lymphocyte count, serum albumin, and C‐reactive protein (CRP) levels, is commonly used to assess nutritional and inflammatory status. However, existing studies have not clarified the association between the CALLY index and prognosis in patients with chronic inflammatory airway diseases (CIADs). This study aims to elucidate the relationship between the CALLY index and the risks of all‐cause and cardiovascular mortality among CIAD patients in the United States. Methods: This investigation included 4128 patients with CIAD from the National Health and Nutrition Examination Survey (NHANES, 1999–2010). The CALLY index was measured only at baseline. We employed weighted Cox proportional hazards regression models to assess the association between the CALLY index and risks of all‐cause and cardiovascular mortality across three progressively adjusted models. To evaluate potential nonlinear dose–response relationships, we applied restricted cubic spline (RCS) models. Additionally, subgroup analyses and sensitivity analyses were conducted to verify the robustness of our findings. Results: Multivariable‐adjusted Model 3 demonstrated that, compared with the lowest quartile, the highest CALLY index quartile showed a significant inverse association with both all‐cause and cardiovascular mortality, with corresponding HRs of 0.36 (95% CI: 0.27–0.47) and 0.33 (95% CI: 0.21–0.51), respectively (both p < 0.05). Conclusions: The CALLY index showed a significant inverse association with all‐cause and cardiovascular mortality among U.S. adults with CIAD, suggesting its potential value as a prognostic tool for risk stratification in this group.
4 August 2026 in American Journal of Respiratory and Critical Care Medicine
28 August 2026 in Medicine
Rationale: Allergic bronchopulmonary aspergillosis (ABPA) is a complex pulmonary disease that results from hypersensitivity reactions triggered in response to A fumigatus . To date, there have been few reports of ABPA patients exhibiting elevated serum carcinoembryonic antigen levels. Moreover, while systemic antifungal treatment often results in substantial side effects when administered to ABPA patients, there has been little published regarding bronchoscopic amphotericin B instillation as an alternative treatment strategy. Patient concerns: We describe an ABPA patient who was repeatedly misdiagnosed with lung cancer. This 60-year-old woman complained of a 5-year history of a recurrent cough with whitish viscous sputum that had recurred and worsened within the 2 days before presentation. This woman had visited hospitals many times during this interval, and pulmonary computed tomography scans had revealed an occupying lesion in the left upper lobe of her lung. This, coupled with her elevated serum carcinoembryonic antigen levels and other lung cancer markers, led to the misdiagnosis of lung cancer. Diagnoses: As we found that she also exhibited elevated serum IgE and circulating eosinophil counts, and Aspergillus was detected through rapid on-site evaluation, we sent a further blood sample for fungal antigen-specific antibody testing. This approach revealed markedly elevated levels of A fumigatus -specific IgE, Aspergillus -specific IgG and IgM, leading to the confirmation of an ABPA diagnosis. Interventions: The patient was administered inhaled budesonide together with antifungal therapy consisting of oral voriconazole and bronchoscopic amphotericin B instillation. She was additionally provided empiric antibiotic treatment to alleviate her cough and reduce phlegm production. Outcomes: Her symptoms and the associated lung lesion improved significantly. Lessons: Bronchoscopic amphotericin B instillation represents a safe and effective approach to treating ABPA, providing a means of increasing local drug concentrations while minimizing the potential for systemic adverse reactions.